Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial

INTRODUCTION: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder for which there are currently no disease-modifying therapies. The neuropathology of PSP is associated with the accumulation of hyperphosphorylated tau in the brain. We have previously shown that protein phosphatase 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivash, Lucy, Bertram, Kelly L, Malpas, Charles B, Marotta, Cassandra, Harding, Ian H, Kolbe, Scott, Fielding, Joanne, Clough, Meaghan, Lewis, Simon J G, Tisch, Stephen, Evans, Andrew H, O’Sullivan, John D, Kimber, Thomas, Darby, David, Churilov, Leonid, Law, Meng, Hovens, Christopher M, Velakoulis, Dennis, O’Brien, Terence J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679117/
https://www.ncbi.nlm.nih.gov/pubmed/34916328
http://dx.doi.org/10.1136/bmjopen-2021-055019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679117/
https://www.ncbi.nlm.nih.gov/pubmed/34916328
http://dx.doi.org/10.1136/bmjopen-2021-055019

Ejemplares similares